Zynerba Pharmaceuticals, Inc.   Report issue

For profit Phase 3
Founded: Devon PA United States (2007)
Status: Acquired by Harmony Biosciences, LLC (2023)

Organization Overview

First Clinical Trial
2018
NCT03614663
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Zynerba Pharmaceuticals, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

cannabidiol (Epidiolex) (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Fragile X Syndrome (Phase 3)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 1